These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 17910631

  • 1. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
    Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM.
    Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
    [Abstract] [Full Text] [Related]

  • 2. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
    Reichardt VL, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P.
    Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
    [Abstract] [Full Text] [Related]

  • 3. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C, Schmidt C, Bornhäuser M, Ehninger G, Schmitz M, Auffermann-Gretzinger S.
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [Abstract] [Full Text] [Related]

  • 4. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
    Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R.
    Blood; 1999 Apr 01; 93(7):2411-9. PubMed ID: 10090953
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy.
    Coscia M, Mariani S, Battaglio S, Di Bello C, Fiore F, Foglietta M, Pileri A, Boccadoro M, Massaia M.
    Leukemia; 2004 Jan 01; 18(1):139-45. PubMed ID: 14574332
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
    Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A.
    Blood; 1999 Jul 15; 94(2):673-83. PubMed ID: 10397734
    [Abstract] [Full Text] [Related]

  • 8. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
    Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F.
    Br J Haematol; 2010 Sep 15; 150(5):554-64. PubMed ID: 20618329
    [Abstract] [Full Text] [Related]

  • 9. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
    Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, Benike CJ, Reichardt V, van Beckhoven A, Rajapaksa R, Engleman EG, Blume KG, Levy R.
    Biol Blood Marrow Transplant; 2000 Sep 15; 6(6):621-7. PubMed ID: 11128812
    [Abstract] [Full Text] [Related]

  • 10. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
    Zeis M, Frenzke H, Schmitz N, Uharek L, Steinmann J.
    Bone Marrow Transplant; 2002 Feb 15; 29(3):213-21. PubMed ID: 11859393
    [Abstract] [Full Text] [Related]

  • 11. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.
    Blood; 2002 Mar 01; 99(5):1517-26. PubMed ID: 11861263
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ.
    Clin Cancer Res; 2003 Nov 01; 9(14):5091-100. PubMed ID: 14613986
    [Abstract] [Full Text] [Related]

  • 17. Transient expansion of peptide-specific lymphocytes producing IFN-gamma after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors.
    Toungouz M, Libin M, Bulté F, Faid L, Lehmann F, Duriau D, Laporte M, Gangji D, Bruyns C, Lambermont M, Goldman M, Velu T.
    J Leukoc Biol; 2001 Jun 01; 69(6):937-43. PubMed ID: 11404379
    [Abstract] [Full Text] [Related]

  • 18. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q.
    Clin Exp Immunol; 2012 Nov 01; 170(2):167-77. PubMed ID: 23039887
    [Abstract] [Full Text] [Related]

  • 19. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
    Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF.
    J Immunother; 2010 Nov 01; 33(2):178-84. PubMed ID: 20145546
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.